Y-mAbs Therapeutics (YMAB) News Today $6.16 -0.02 (-0.32%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor January 16, 2025 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)January 15, 2025 | americanbankingnews.comY-Mabs Therapeutics (YMAB) Receives a Buy from H.C. WainwrightJanuary 13, 2025 | markets.businessinsider.comY-Mabs Therapeutics (YMAB) Receives a Buy from Truist FinancialJanuary 13, 2025 | markets.businessinsider.comY-mAbs Therapeutics Updates on Business and Clinical TrialsJanuary 13, 2025 | tipranks.comHC Wainwright Reiterates Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comY-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The plan invJanuary 13, 2025 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $20.89 Consensus Target Price from AnalystsJanuary 13, 2025 | americanbankingnews.comJonesTrading Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)January 11, 2025 | markets.businessinsider.comY-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from WedbushWedbush restated an "outperform" rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Friday.January 10, 2025 | marketbeat.comY-mAbs Therapeutics, Inc.: Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business UnitJanuary 10, 2025 | finanznachrichten.deY-mAbs Therapeutics appoints Gentilcore as SVP, head of DANYELZA unitJanuary 10, 2025 | markets.businessinsider.comY-mAbs Therapeutics announces milestones for 2025January 10, 2025 | markets.businessinsider.comCorrecting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 PrioritiesJanuary 10, 2025 | globenewswire.comY-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business UnitJanuary 10, 2025 | globenewswire.comY-mAbs Provides Strategic Business Update and 2025 PrioritiesJanuary 10, 2025 | globenewswire.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Buy" by AnalystsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has earned a consensus recommendation of "Buy" from the ten research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy rJanuary 10, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by State Street CorpState Street Corp grew its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 50.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,209,781 shares of the company's stock after acquiring an additional 405,169 shares during the period. SDecember 25, 2024 | marketbeat.comY-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23, 2024 | globenewswire.comWe're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash WiselyDecember 20, 2024 | finance.yahoo.comY-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdlesDecember 19, 2024 | uk.investing.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of "Buy" by BrokeragesShares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have received a consensus rating of "Buy" from the ten brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have giveDecember 16, 2024 | marketbeat.comPositive Outlook and Investment Potential for Y-Mabs Therapeutics: Buy Rating with Promising Preclinical and Clinical DevelopmentsDecember 14, 2024 | markets.businessinsider.comPromising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs TherapeuticsDecember 13, 2024 | markets.businessinsider.comY-mAbs Therapeutics (NASDAQ:YMAB) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating on shares of Y-mAbs Therapeutics in a research report on Wednesday.December 11, 2024 | marketbeat.comPoint72 Asset Management L.P. Decreases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Point72 Asset Management L.P. decreased its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 73.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,383 shares of the company's sDecember 11, 2024 | marketbeat.comPromising Preclinical Results of Y-Mabs Therapeutics’ CD38 SADA Platform Justify Buy RatingDecember 10, 2024 | markets.businessinsider.comBrookline Capital Management Predicts YMAB FY2024 EarningsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a note issued to investors on Wednesday, December 4th. Brookline Capital Management analyst K. Dolliver antiDecember 9, 2024 | marketbeat.comY-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual MeetingDecember 7, 2024 | globenewswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Rating Increased to Strong-Buy at Brookline Capital ManagementBrookline Capital Management raised shares of Y-mAbs Therapeutics to a "strong-buy" rating in a report on Wednesday.December 6, 2024 | marketbeat.comY-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potentialDecember 5, 2024 | markets.businessinsider.comBrookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy RecommendationDecember 5, 2024 | msn.comCaligan Partners LP Raises Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Caligan Partners LP boosted its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 105.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,195,253 shares of the company's stockDecember 1, 2024 | marketbeat.comY-mAbs to Participate at Citi’s 2024 Global Healthcare ConferenceNovember 27, 2024 | markets.businessinsider.comY-mAbs to Participate at Citi's 2024 Global Healthcare ConferenceNovember 27, 2024 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Sells 81,830 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Connor Clark & Lunn Investment Management Ltd. trimmed its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 46.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,225 shares of theNovember 27, 2024 | marketbeat.comY-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder SettlementNovember 22, 2024 | benzinga.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Moderate Buy" by BrokeragesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have giNovember 21, 2024 | marketbeat.comOppenheimer Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Outperform RecommendationNovember 19, 2024 | msn.comInstitutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growthNovember 18, 2024 | finance.yahoo.comY-mAbs Therapeutics initiated with an Outperform at OppenheimerNovember 18, 2024 | markets.businessinsider.comY-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapiesNovember 18, 2024 | msn.comY-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Analysts at OppenheimerOppenheimer started coverage on Y-mAbs Therapeutics in a report on Monday. They issued an "outperform" rating and a $23.00 target price on the stock.November 18, 2024 | marketbeat.comY-mAbs: Strategic Partnership and Strong Financial Outlook Reinforce Buy RatingNovember 16, 2024 | markets.businessinsider.comY-mAbs Therapeutics' (YMAB) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comCantor Fitzgerald Has Positive View of YMAB FY2024 EarningsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for Y-mAbs Therapeutics in a research report issued on Monday, November 11th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earningsNovember 14, 2024 | marketbeat.comTruist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)November 12, 2024 | markets.businessinsider.comY-Mabs Therapeutics: Promising Pipeline Developments and Strong Revenue Projections Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comY-Mabs Therapeutics Faces Uncertain Growth Amid Declining Danyelza Sales and Market ChallengesNovember 9, 2024 | markets.businessinsider.com Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Media Mentions By Week YMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YMAB News Sentiment▼0.160.44▲Average Medical News Sentiment YMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YMAB Articles This Week▼24▲YMAB Articles Average Week Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies COLL News Today ALVR News Today SYRE News Today ELVN News Today GYRE News Today ADPT News Today NTLA News Today ZYME News Today RCKT News Today PSTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YMAB) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YMAB Stock Alerts